# Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

> **NCT03384914** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 119 (actual)

## Conditions studied

- Breast Cancer Female
- Breast Cancer, Male
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage III
- Residual Disease
- HER2-positive Breast Cancer
- HER2 Positive Breast Carcinoma

## Interventions

- **BIOLOGICAL:** DC1 Vaccine
- **BIOLOGICAL:** WOKVAC Vaccine

## Key facts

- **NCT ID:** NCT03384914
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-19
- **Primary completion:** 2025-12-22
- **Final completion:** 2027-12
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03384914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03384914, "Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03384914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*